Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment

We evaluated patients with relapsed multiple myeloma with renal impairment (RI) treated with standard of care idecabtagene vicleucel (ide-cel), as outcomes with chimeric antigen receptor (CAR) T-cell therapy are unknown in this population. RI was defined as creatinine clearance (CrCl) <50 mL/min...

全面介紹

書目詳細資料

發表在:	Haematologica
Main Authors:	Surbhi Sidana, Lauren C. Peres, Hamza Hashmi, Hitomi Hosoya, Christopher Ferreri, Jack Khouri, Danai Dima, Shebli Atrash, Peter Voorhees, Gary Simmons, Douglas W. Sborov, Nilesh Kalariya, Vanna Hovanky, Sushma Bharadwaj, David Miklos, Charlotte Wagner, Mehmet H. Kocoglu, Gurbakhash Kaur, James A. Davis, Shonali Midha, Murali Janakiram, Ciara Freeman, Melissa Alsina, Frederick Locke, Rebecca Gonzalez, Yi Lin, Joseph McGuirk, Aimaz Afrough, Leyla Shune, Krina K. Patel, Doris K. Hansen
格式:	Article
語言:	英语
出版:	Ferrata Storti Foundation 2023-09-01
在線閱讀:	https://haematologica.org/article/view/11274